{
    "root": "314914d1-c029-cfe6-e063-6394a90a54f4",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "ERIBULIN MESYLATE",
    "value": "20250327",
    "ingredients": [
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_30879"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32145"
        },
        {
            "name": "HYDROCHLORIC ACID",
            "code": "QTT17582CB",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_37527"
        },
        {
            "name": "ERIBULIN MESYLATE",
            "code": "AV9U0660CW",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70710"
        }
    ],
    "indications": {
        "text": "eribulin mesylate injection microtubule inhibitor indicated treatment patients : metastatic breast cancer previously received least two chemotherapeutic regimens treatment metastatic disease . prior therapy included anthracycline taxane either adjuvant metastatic setting . ( 1.1 ) unresectable metastatic liposarcoma received prior anthracycline-containing regimen . ( 1.2 )",
        "doid_entities": [
            {
                "text": "breast cancer (DOID:1612)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1612"
            },
            {
                "text": "cancer (DOID:162)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_162"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "liposarcoma (DOID:3382)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3382"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "administer 1.4 mg/m 2 intravenously 2 5 minutes days 1 8 21-day cycle . ( 2.1 ) reduce dose patients hepatic impairment moderate severe renal impairment . ( 2.1 ) mix drugs administer dextrose-containing solutions . ( 2.3 )",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": "ndc 0143-9167-01 injection : 1 mg/2 ml , single-dose vial . one vial per carton . store 25\u00b0c ( 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0 c ( 59\u00b0 86\u00b0 f ) [ usp controlled room temperature ] . freeze refrigerate . store vials original cartons . eribulin mesylate injection cytotoxic . follow applicable special handling disposal procedures . 1",
    "adverseReactions": "none .",
    "indications_original": "Eribulin mesylate injection is a microtubule inhibitor indicated for the treatment of patients with: Metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included an anthracycline and a taxane in either the adjuvant or metastatic setting. ( 1.1 ) Unresectable or metastatic liposarcoma who have received a prior anthracycline-containing regimen. ( 1.2 )",
    "contraindications_original": "Administer 1.4 mg/m 2 intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle. ( 2.1 ) Reduce dose in patients with hepatic impairment or with moderate or severe renal impairment. ( 2.1 ) Do not mix with other drugs or administer with dextrose-containing solutions. ( 2.3 )",
    "warningsAndPrecautions_original": "NDC 0143-9167-01\u00a0 \u00a0 \u00a0\u00a0\n                  Injection: 1 mg/2 mL, in a single-dose vial. One vial per carton.\n                  Store at 25\u00b0C (77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0 C (59\u00b0 to\u00a086\u00b0 F) [see USP Controlled Room Temperature]. Do not freeze or refrigerate. Store the vials in their original cartons.\n                  Eribulin mesylate injection is a cytotoxic drug. Follow applicable special handling and disposal procedures.\n \n  1",
    "adverseReactions_original": "None.",
    "drug": [
        {
            "name": "ERIBULIN MESYLATE",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_70710"
        }
    ]
}